 Aileron Therapeutics NASDAQ:ALRNs stock had its buy rating restated by HC Wainwright in a report released on Monday, AnalystRatings.com reports. They currently have a 2.00 price target on the stock. HC Wainwrights target price would indicate a potential upside of 72.41 from the stocks previous close. Several other research firms also recently weighed in on ... 